COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Indocyangreen Elimination in Cirrhosis and Acute Liver Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00245310
Recruitment Status : Completed
First Posted : October 27, 2005
Last Update Posted : October 11, 2010
Sponsor:
Information provided by:
Heidelberg University

Brief Summary:

Indocyangreen (ICG)is totally biliary eliminated and corresponds to hepatocyte function and liver perfusion.

The ICG-clearance will be evaluated as a prognostic marker in liver disease.


Condition or disease Intervention/treatment
Acute Liver Failure Liver Cirrhosis Procedure: Indocyangreen (ICG) clearance

Detailed Description:
patients with acute liver failure or advanced liver disease will be studied. ICG-clearance will be correlated with established clinical scores and outcome.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of the Indocyangreen Elimination as a Prognostic Marker in Decompensated Cirrhosis and Acute Liver Failure
Study Start Date : October 2005
Actual Primary Completion Date : October 2010
Actual Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cirrhosis





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Criteria

Inclusion Criteria:

  • acute liver failure OR end-stage liver disease
  • normal hepatic perfusion by doppler ultrasound

Exclusion Criteria:

  • portal vein thrombosis
  • allergy to ICG or iodine
  • thyroid disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00245310


Locations
Layout table for location information
Germany
University of Heidelberg
Heidelberg, Germany, 69120
Sponsors and Collaborators
Heidelberg University
Investigators
Layout table for investigator information
Principal Investigator: Jens Encke, PD Dr. med. Heidelberg University
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00245310    
Other Study ID Numbers: LiMON
First Posted: October 27, 2005    Key Record Dates
Last Update Posted: October 11, 2010
Last Verified: November 2008
Keywords provided by Heidelberg University:
ICG clearance
liver cirrhosis
acute liver failure
prognosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Cirrhosis
Liver Failure
Hepatic Insufficiency
Liver Failure, Acute
Fibrosis
Pathologic Processes
Liver Diseases
Digestive System Diseases